Cassava Sciences Releases a Public Statement Regarding Recent Allegations
“Let me be very clear: I think these allegations are false,” said
Cassava Sciences’ full public statement is now available as an audio file made by
||‘Investors’ page of the Company’s website
The Audio File will also be archived on the ‘Investors’ page of the Company’s website: https://www.CassavaSciences.com.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years,
For More Information Contact:
Cautionary Note Regarding Forward-Looking Statements:
This news release includes forward looking statements including but not limited to those regarding the timing of the initiation and subsequent progress of our pivotal Phase 3 trial and its likelihood of success, the timing of announcement of the results of our open label study, the FDA response to the Citizen’s Petition, the initiation and progression of the
Drug development involves a high degree of risk, and historically only a small number of research and development programs result in commercialization of a product. Clinical results from our earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish. Such statements are based largely on our current expectations and projections about future events.
Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, the severity and duration of health care precautions given the COVID-19 pandemic, any unanticipated impacts of the pandemic on our business operations, and including those described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended
For further information regarding these and other risks related to our business, investors should consult our filings with the
Source: Cassava Sciences, Inc.